Please assess the completion status of the following clinical trial:

Trial Title: MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* At least 65 years of age who are eligible for the study vaccines;~* Who have given written informed consent at the time of enrollment);~* Those who are available for all the visits scheduled in the study;~* Subjects In good health as determined by medical history, physical examination and clinical judgment of the investigator~Exclusion Criteria:~* History of egg allergy~* History of influenza vaccination in previous 6 months~* History of any pneumococcal vaccination~* Documented S. pneumonia infection in the previous 5 years~* Chemotherapy for malignancy within the past 30 days~* High-dose systemic steroid (prednisone ≥0.5 mg/kg/day) in the past 30 days~* Receipt of blood product within 6 months before enrollment~* Significant acute or chronic infection within the previous 7 days or fever within the previous day~* Any serious chronic or progressive disease~* Any condition that might interfere with the study results.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Fluad alone (Type: ACTIVE_COMPARATOR): 56 Fluad recipients: one vaccine injection administered on Day 0
- Fluad and PPV23 on the different arms (Type: ACTIVE_COMPARATOR): 56 concomitant Fluad-PPV23 recipients on the different arms: one dose of each vaccine administered on Day 0
- Fluad and PPV23 on the same arm (Type: ACTIVE_COMPARATOR): 56 concomitant Fluad-PPV23 recipients on the same arm with 1 inch distance: one dose of each vaccine administered on Day 0
- PPV23 alone (Type: ACTIVE_COMPARATOR): 56 PPV23 recipients: one vaccine injection administered on Day 0

Based on this trial design, predict the completion outcome and termination type (if applicable).